300439 美康生物
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)8.0089.8208.1759.00020.110
总资产报酬率 ROA (%)6.3637.2555.5325.2438.563
投入资产回报率 ROIC (%)7.4508.6316.6756.35011.782

边际利润分析
销售毛利率 (%)45.79944.60438.15140.47536.850
营业利润率 (%)17.78714.8009.1869.7587.512
息税前利润/营业总收入 (%)17.66615.5889.16510.85217.398
净利润/营业总收入 (%)15.87613.7608.2448.44512.753

收益指标分析
经营活动净收益/利润总额(%)84.39775.904126.522109.50853.120
价值变动净收益/利润总额(%)5.8265.0491.736-1.2494.913
营业外收支净额/利润总额(%)1.8705.601-2.389-0.67250.174

偿债能力分析
流动比率 (X)3.0712.7162.1111.8941.130
速动比率 (X)2.6242.3461.8891.6950.947
资产负债率 (%)19.16222.42629.69733.46548.159
带息债务/全部投入资本 (%)2.4695.50313.33217.591--
股东权益/带息债务 (%)3,820.7261,666.151630.987450.029169.960
股东权益/负债合计 (%)423.090346.959235.857195.186104.754
利息保障倍数 (X)-38.447-170.99347.2459.3657.492

营运能力分析
应收账款周转天数 (天)110.599132.059117.634133.2590.000
存货周转天数 (天)92.25882.19550.21062.4940.000